Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition
has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma …

Raf-mitogen-activated protein kinase (Raf-MAPK) pathway inhibition with the BRAF
inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK inhibitor, has …

The inhibition of the mitogen-activated protein kinases signalling pathway through combined
use of BRAF and MEK inhibitors (BRAFi+ MEKi) represents an established therapeutic …

Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in
the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment …

BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

The discovery of activating BRAF mutations in melanomas has led to the investigation of
small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within …

Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …